Bayer : Mixed Q3 results –2023 guidance confirmed but extremely strong Q4 needed
>Mixed Q3 results as CS and CH disappoint - Pharma ahead of expectations - Q3 2023 results were mixed with disappointing earnings in the Crop Science and Consumer Health divisions but earnings ahead of expectations in Pharma. Despite already low expectations, seasonally weak CropScience adj. EBITDA came in below our forecasts (€ 52m) and significantly below the consensus (€ 280m), with a loss of € 24m. Pharma came in about 6% above expectations at € 1,438m while Consu...Bayer is a life sciences group based in Germany. Co.'s operations are organized along three divisions: Pharmaceuticals (engaged in prescription pharmaceuticals for cardiology and women's healthcare); Consumer Health (engaged in non-prescription products in dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories); and CropScience (engaged in the development of seeds and plant traits; crop protection; and for gardens, the green industry and non-agricultural pest control). Co. also maintains an Animal Health business unit engaged in the development of products for farm and companion animals.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.